Contributions
Abstract: PB2532
Type: Publication Only
Background
The anemia in lymphoproliferative disorder’s (LPD) patients is a frequent symptom and can decrease the efficacy of antitumor therapy (AT-therapy), overall survival and quality of life. Anemia’s pathogenesis is based on suppression by proinflammatory cytokines and decreasing erythroid precursor’s sensitivity to serum erythropoietin. More over AT-therapy can play significant role in increasing of frequency and severity of anemia - chemotherapy-induced anemia.
Aims
To definite of frequency of anemia in newly diagnosticated of LPD patients and evaluate the influence of antitumor therapy on frequency and severity of anemia.
Methods
We have examined the following patients in the age of 24-85 years: multiple myeloma (MM) in II and III st. (n=119), Non-Hodgkin's lymphoma (NHL) in III-IV st. (n=72) and chronic lymphocytic leukemia (CLL) in B or C st. (n=147). Clinical blood test (hemogram) was examined more then twice before AT-therapy and during 1-3 cycles of therapy. All patients were administrated different therapy: patients with multiple myeloma – VD, VСP, VMP, PAD; patients with Non-Hodgkin's lymphoma – RB, VRB, R-FC, R-CHOP, R-CVP; patients with chronic lymphocytic leukemia – RB, FC-R, R-CHOP, R-Chlorambucil.
Results
We have accessed the rate of anemia in the group of patients with MM (n=119) was 56.3% (n=67) but after AT-therapy it significantly increased to 79.0% (n=94; p<0.01); in the group of NHL (n=72) the rate of anemia increased from 38.9% (n=28) to 65.3% (n=47; p<0.01); in the group of CLL (n=147) the rate of anemia increased from 33.3% (n=49) to 68.7% (n=101; p<0.01). Besides the grade of anemia (by WHO hematological toxicity scale) also increased. So, the number of patients with anemia (grade 1) increased from 17.5% (n=59) to 27.2% (n=92; p<0.01); the number of patients with anemia (grade 2) increased from 13.6% (n=46) to 24.9% (n=84; p<0.01); the number of patients with anemia (grade 3) increased from 7.1% (n=24) to 11.8% (n=40; p<0.05); the number of patients with anemia (grade 4) increased from 4.4% (n=15) to 7.7% (n=26; p<0.05). Too impotent to emphasize that 20.4% (n=69) of patients were administrated 1-6 dosages of red blood cells transfusions.
Conclusion
In this study were revealed the high rate of chemotherapy-induced anemia in newly diagnosed LPD patients and increasing of it during the AT-therapy that might to need administration of RBC transfusions.
Session topic: 32. Transfusion medicine
Keyword(s): Anemia, Chemotherapy-induced anemia, Hemoglobin, Lymphoproliferative disorder
Abstract: PB2532
Type: Publication Only
Background
The anemia in lymphoproliferative disorder’s (LPD) patients is a frequent symptom and can decrease the efficacy of antitumor therapy (AT-therapy), overall survival and quality of life. Anemia’s pathogenesis is based on suppression by proinflammatory cytokines and decreasing erythroid precursor’s sensitivity to serum erythropoietin. More over AT-therapy can play significant role in increasing of frequency and severity of anemia - chemotherapy-induced anemia.
Aims
To definite of frequency of anemia in newly diagnosticated of LPD patients and evaluate the influence of antitumor therapy on frequency and severity of anemia.
Methods
We have examined the following patients in the age of 24-85 years: multiple myeloma (MM) in II and III st. (n=119), Non-Hodgkin's lymphoma (NHL) in III-IV st. (n=72) and chronic lymphocytic leukemia (CLL) in B or C st. (n=147). Clinical blood test (hemogram) was examined more then twice before AT-therapy and during 1-3 cycles of therapy. All patients were administrated different therapy: patients with multiple myeloma – VD, VСP, VMP, PAD; patients with Non-Hodgkin's lymphoma – RB, VRB, R-FC, R-CHOP, R-CVP; patients with chronic lymphocytic leukemia – RB, FC-R, R-CHOP, R-Chlorambucil.
Results
We have accessed the rate of anemia in the group of patients with MM (n=119) was 56.3% (n=67) but after AT-therapy it significantly increased to 79.0% (n=94; p<0.01); in the group of NHL (n=72) the rate of anemia increased from 38.9% (n=28) to 65.3% (n=47; p<0.01); in the group of CLL (n=147) the rate of anemia increased from 33.3% (n=49) to 68.7% (n=101; p<0.01). Besides the grade of anemia (by WHO hematological toxicity scale) also increased. So, the number of patients with anemia (grade 1) increased from 17.5% (n=59) to 27.2% (n=92; p<0.01); the number of patients with anemia (grade 2) increased from 13.6% (n=46) to 24.9% (n=84; p<0.01); the number of patients with anemia (grade 3) increased from 7.1% (n=24) to 11.8% (n=40; p<0.05); the number of patients with anemia (grade 4) increased from 4.4% (n=15) to 7.7% (n=26; p<0.05). Too impotent to emphasize that 20.4% (n=69) of patients were administrated 1-6 dosages of red blood cells transfusions.
Conclusion
In this study were revealed the high rate of chemotherapy-induced anemia in newly diagnosed LPD patients and increasing of it during the AT-therapy that might to need administration of RBC transfusions.
Session topic: 32. Transfusion medicine
Keyword(s): Anemia, Chemotherapy-induced anemia, Hemoglobin, Lymphoproliferative disorder